Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines

doi:10.1084/jem.183.4.1357

This Article

	Full Text (PDF, 853K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Mayordomo, J. I.
	Articles by DeLeo, A. B.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Mayordomo, J. I.
	Articles by DeLeo, A. B.


Social Bookmarking

	What's this?

ARTICLES

Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines

JI Mayordomo, DJ Loftus, H Sakamoto, CM De Cesare, PM Appasamy, MT Lotze, WJ Storkus, E Appella and AB DeLeo
Department of Genetics and Biochemistry, School of Medicine, University of Pittsburgh, Pennsylvania 15213-2582, USA.

The BALB/c Meth A sarcoma carries a p53 missense mutation at codon 234, which occurs in a peptide, termed 234CM, capable of being presented to cytotoxic T lymphocytes (CTL) by H-2Kd molecules (Noguchi, Y., E.C. Richards, Y.-T. Chen, and L.J. Old. 1994. Proc. Natl. Acad. Sci. USA. 91:3171-3175). Immunization of BALB/c mice with bone marrow-derived dendritic cells (DC), generated in the presence of granulocyte macrophage colony-stimulating factor and interleukin 4, and prepulsed with the Meth A p53 mutant peptide, induced CTL that specifically recognized peptide-pulsed P815 cells, as well as Meth A cells naturally expressing this epitope. Immunization with this vaccine also protected naive mice from a subsequent tumor challenge, and it inhibited tumor growth in mice bearing day 7 subcutaneous Meth A tumors. We additionally determined that immunization of BALB/c mice with DC pulsed with the p53 peptide containing the wild-type residue at position 234, 234CW, induced peptide-specific CTL that reacted against several methylcholanthrene-induced BALB/c sarcomas, including CMS4 sarcoma, and rejection of CMS4 sarcoma in vaccination and therapy (day 7) protocols. These results support the efficacy of DC-based, p53-derived peptide vaccines for the immunotherapy of cancer. The translational potential of this strategy is enhanced by previous reports showing that DC can readily be generated from human peripheral blood lymphocytes.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Petersen, J., Wurzbacher, S. J., Williamson, N. A., Ramarathinam, S. H., Reid, H. H., Nair, A. K. N., Zhao, A. Y., Nastovska, R., Rudge, G., Rossjohn, J., Purcell, A. W. (2009). Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc. Natl. Acad. Sci. USA 106: 2776-2781 [Abstract] [Full Text]
Ito, D., Albers, A., Zhao, Y. X., Visus, C., Appella, E., Whiteside, T. L., DeLeo, A. B. (2006). The Wild-Type Sequence (wt) p5325-35 Peptide Induces HLA-DR7 and HLA-DR11-Restricted CD4+ Th Cells Capable of Enhancing the Ex Vivo Expansion and Function of Anti-wt p53264-272 Peptide CD8+ T Cells. J. Immunol. 177: 6795-6803 [Abstract] [Full Text]
Williamson, N. A., Rossjohn, J., Purcell, A. W. (2006). Tumors reveal their secrets to cytotoxic T cells. Proc. Natl. Acad. Sci. USA 103: 14649-14650 [Full Text]
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., Menander, K., Chada, S., Gabrilovich, D. I. (2006). Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer. Clin. Cancer Res. 12: 878-887 [Abstract] [Full Text]
Carbone, D. P., Ciernik, I. F., Kelley, M. J., Smith, M. C., Nadaf, S., Kavanaugh, D., Maher, V. E., Stipanov, M., Contois, D., Johnson, B. E., Pendleton, C. D., Seifert, B., Carter, C., Read, E. J., Greenblatt, J., Top, L. E., Kelsey, M. I., Minna, J. D., Berzofsky, J. A. (2005). Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome. JCO 23: 5099-5107 [Abstract] [Full Text]
Terme, M., Borg, C., Guilhot, F., Masurier, C., Flament, C., Wagner, E. F., Caillat-Zucman, S., Bernheim, A., Turhan, A. G., Caignard, A., Zitvogel, L. (2005). BCR/ABL Promotes Dendritic Cell-Mediated Natural Killer Cell Activation. Cancer Res. 65: 6409-6417 [Abstract] [Full Text]
Tokunaga, N., Murakami, T., Endo, Y., Nishizaki, M., Kagawa, S., Tanaka, N., Fujiwara, T. (2005). Human Monocyte-Derived Dendritic Cells Pulsed with Wild-Type p53 Protein Efficiently Induce CTLs against p53 Overexpressing Human Cancer Cells. Clin. Cancer Res. 11: 1312-1318 [Abstract] [Full Text]
Daftarian, P., Song, G.-Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., Ellenhorn, J. D. I. (2004). Two Distinct Pathways of Immuno-Modulation Improve Potency of p53 Immunization in Rejecting Established Tumors. Cancer Res. 64: 5407-5414 [Abstract] [Full Text]
Murakami, T., Tokunaga, N., Waku, T., Gomi, S., Kagawa, S., Tanaka, N., Fujiwara, T. (2004). Antitumor Effect of Intratumoral Administration of Bone Marrow-Derived Dendritic Cells Transduced with Wild-Type p53 Gene. Clin. Cancer Res. 10: 3871-3880 [Abstract] [Full Text]
Terme, M., Tomasello, E., Maruyama, K., Crepineau, F., Chaput, N., Flament, C., Marolleau, J.-P., Angevin, E., Wagner, E. F., Salomon, B., Lemonnier, F. A., Wakasugi, H., Colonna, M., Vivier, E., Zitvogel, L. (2004). IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules. J. Immunol. 172: 5957-5966 [Abstract] [Full Text]
Monzavi-Karbassi, B., Luo, P., Jousheghany, F., Torres-Quinones, M., Cunto-Amesty, G., Artaud, C., Kieber-Emmons, T. (2004). A Mimic of Tumor Rejection Antigen-Associated Carbohydrates Mediates an Antitumor Cellular Response. Cancer Res. 64: 2162-2166 [Abstract] [Full Text]
Lomas, M., Liauw, W., Packham, D., Williams, K., Kelleher, A., Zaunders, J., Ward, R. (2004). Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Ann Oncol 15: 324-329 [Abstract] [Full Text]
Wu, S.-F., Liu, T.-M., Lin, Y.-C., Sytwu, H.-K., Juan, H.-F., Chen, S.-T., Shen, K.-L., Hsi, S.-C., Hsieh, S.-L. (2004). Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J. Leukoc. Biol. 75: 293-306 [Abstract] [Full Text]
Cuadrado, S. P., Moreno Koch, M. d. C., Perez, C. F., Castejon Castan, L. M., Villalobos, C. P., Gonzalez Mateos, M. J., Olmos, C. L. (2003). Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound. Clin. Cancer Res. 9: 5776-5785 [Abstract] [Full Text]
Tatsumi, T., Huang, J., Gooding, W. E., Gambotto, A., Robbins, P. D., Vujanovic, N. L., Alber, S. M., Watkins, S. C., Okada, H., Storkus, W. J. (2003). Intratumoral Delivery of Dendritic Cells Engineered to Secrete Both Interleukin (IL)-12 and IL-18 Effectively Treats Local and Distant Disease in Association with Broadly Reactive Tc1-type Immunity. Cancer Res. 63: 6378-6386 [Abstract] [Full Text]
Chikamatsu, K., Albers, A., Stanson, J., Kwok, W. W., Appella, E., Whiteside, T. L., DeLeo, A. B. (2003). p53110-124-specific Human CD4+ T-helper Cells Enhance in Vitro Generation and Antitumor Function of Tumor-reactive CD8+ T Cells. Cancer Res. 63: 3675-3681 [Abstract] [Full Text]
Berberich, C., Ramirez-Pineda, J. R., Hambrecht, C., Alber, G., Skeiky, Y. A. W., Moll, H. (2003). Dendritic Cell (DC)-Based Protection Against an Intracellular Pathogen Is Dependent Upon DC-Derived IL-12 and Can Be Induced by Molecularly Defined Antigens. J. Immunol. 170: 3171-3179 [Abstract] [Full Text]
Espenschied, J., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., Ellenhorn, J. D. I. (2003). CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model. J. Immunol. 170: 3401-3407 [Abstract] [Full Text]
Zwaveling, S., Vierboom, M. P. M., Ferreira Mota, S. C., Hendriks, J. A., Ooms, M. E., Sutmuller, R. P. M., Franken, K. L. M. C., Nijman, H. W., Ossendorp, F., van der Burg, S. H., Offringa, R., Melief, C. J. M. (2002). Antitumor Efficacy of Wild-Type p53-specific CD4+ T-Helper Cells. Cancer Res. 62: 6187-6193 [Abstract] [Full Text]
Tatsumi, T., Gambotto, A., Robbins, P. D., Storkus, W. J. (2002). Interleukin 18 Gene Transfer Expands the Repertoire of Antitumor Th1-type Immunity Elicited by Dendritic Cell-based Vaccines in Association with Enhanced Therapeutic Efficacy. Cancer Res. 62: 5853-5858 [Abstract] [Full Text]
Bontkes, H. J., de Gruijl, T. D., Schuurhuis, G. J., Scheper, R. J., Meijer, C. J. L. M., Hooijberg, E. (2002). Expansion of dendritic cell precursors from human CD34+ progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J. Leukoc. Biol. 72: 321-329 [Abstract] [Full Text]
Ikuta, Y., Katayama, N., Wang, L., Okugawa, T., Takahashi, Y., Schmitt, M., Gu, X., Watanabe, M., Akiyoshi, K., Nakamura, H., Kuribayashi, K., Sunamoto, J., Shiku, H. (2002). Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99: 3717-3724 [Abstract] [Full Text]
van der Burg, S. H., Menon, A. G, Redeker, A., Bonnet, M.-C., Drijfhout, J. W., Tollenaar, R. A. E. M., van de Velde, C. J. H., Moingeon, P., Kuppen, P. J. K., Offringa, R., Melief, C. J. M. (2002). Induction of p53-specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine. Clin. Cancer Res. 8: 1019-1027 [Abstract] [Full Text]
Yasuda, M., Takenoyama, M., Obata, Y., Sugaya, M., So, T., Hanagiri, T., Sugio, K., Yasumoto, K. (2002). Tumor-infiltrating B Lymphocytes as a Potential Source of Identifying Tumor Antigen in Human Lung Cancer. Cancer Res. 62: 1751-1756 [Abstract] [Full Text]
Hoffmann, T. K., Loftus, D. J., Nakano, K., Maeurer, M. J., Chikamatsu, K., Appella, E., Whiteside, T. L., DeLeo, A. B. (2002). The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264-272 Epitope. J. Immunol. 168: 1338-1347 [Abstract] [Full Text]
Parajuli, P., Pisarev, V., Sublet, J., Steffel, A., Varney, M., Singh, R., LaFace, D., Talmadge, J. E. (2001). Immunization with Wild-Type p53 Gene Sequences Coadministered with Flt3 Ligand Induces an Antigen-specific Type 1 T-Cell Response. Cancer Res. 61: 8227-8234 [Abstract] [Full Text]
Armstrong, A C, Hawkins, R E (2001). Vaccines in oncology: background and clinical potential. Br. J. Radiol. 74: 991-1002 [Abstract] [Full Text]
Lambert, L. A., Gibson, G. R., Maloney, M., Durell, B., Noelle, R. J., Barth, R. J. Jr. (2001). Intranodal Immunization with Tumor Lysate-pulsed Dendritic Cells Enhances Protective Antitumor Immunity. Cancer Res. 61: 641-646 [Abstract] [Full Text]
Brunner, C., Seiderer, J., Schlamp, A., Bidlingmaier, M., Eigler, A., Haimerl, W., Lehr, H.-A., Krieg, A. M., Hartmann, G., Endres, S. (2000). Enhanced Dendritic Cell Maturation by TNF-{alpha} or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo. J. Immunol. 165: 6278-6286 [Abstract] [Full Text]
Hoffmann, T. K., Nakano, K., Elder, E. M., Dworacki, G., Finkelstein, S. D., Appella, E., Whiteside, T. L., DeLeo, A. B. (2000). Generation of T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in Cancer Patients: Implications for Immunoselection of Epitope Loss Variants. J. Immunol. 165: 5938-5944 [Abstract] [Full Text]
Vierboom, M. P. M., Zwaveling, S., Bos, G. M. J., Ooms, M., Krietemeijer, G. M., Melief, C. J. M., Offringa, R. (2000). High Steady-State Levels of p53 Are Not a Prerequisite for Tumor Eradication by Wild-Type p53-specific Cytotoxic T Lymphocytes. Cancer Res. 60: 5508-5513 [Abstract] [Full Text]
Kikuchi, T., Moore, M. A. S., Crystal, R. G. (2000). Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96: 91-99 [Abstract] [Full Text]
Fedoseyeva, E. V., Boisgerault, F., Anosova, N. G., Wollish, W. S., Arlotta, P., Jensen, P. E., Ono, S. J., Benichou, G. (2000). CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice. J. Immunol. 164: 5641-5651 [Abstract] [Full Text]
Linette, G. P., Shankara, S., Longerich, S., Yang, S., Doll, R., Nicolette, C., Preffer, F. I., Roberts, B. L., Haluska, F. G. (2000). In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma. J. Immunol. 164: 3402-3412 [Abstract] [Full Text]
Eura, M., Chikamatsu, K., Katsura, F., Obata, A., Sobao, Y., Takiguchi, M., Song, Y., Appella, E., Whiteside, T. L., DeLeo, A. B. (2000). A Wild-type Sequence p53 Peptide Presented by HLA-A24 Induces Cytotoxic T Lymphocytes that Recognize Squamous Cell Carcinomas of the Head and Neck. Clin. Cancer Res. 6: 979-986 [Abstract] [Full Text]
Liu, X., Peralta, E. A., Ellenhorn, J. D. I., Diamond, D. J. (2000). Targeting of Human p53-overexpressing Tumor Cells by an HLA A*0201-restricted Murine T-Cell Receptor Expressed in Jurkat T Cells. Cancer Res. 60: 693-701 [Abstract] [Full Text]
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., Carbone, D. P. (1999). Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by Improving Endogenous Dendritic Cell Function. Clin. Cancer Res. 5: 2963-2970 [Abstract] [Full Text]
Kaplan, J. M., Yu, Q., Piraino, S. T., Pennington, S. E., Shankara, S., Woodworth, L. A., Roberts, B. L. (1999). Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens. J. Immunol. 163: 699-707 [Abstract] [Full Text]
Chikamatsu, K., Nakano, K., Storkus, W. J., Appella, E., Lotze, M. T., Whiteside, T. L., DeLeo, A. B. (1999). Generation of Anti-p53 Cytotoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells. Clin. Cancer Res. 5: 1281-1288 [Abstract] [Full Text]
Men, Y., Miconnet, I., Valmori, D., Rimoldi, D., Cerottini, J.-C., Romero, P. (1999). Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/Kb Transgenic Mice. J. Immunol. 162: 3566-3573 [Abstract] [Full Text]
De Veerman, M., Heirman, C., Van Meirvenne, S., Devos, S., Corthals, J., Moser, M., Thielemans, K. (1999). Retrovirally Transduced Bone Marrow-Derived Dendritic Cells Require CD4+ T Cell Help to Elicit Protective and Therapeutic Antitumor Immunity. J. Immunol. 162: 144-151 [Abstract] [Full Text]
Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Haussler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P.-M., Sherman, L. A. (1998). The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope. JEM 188: 1017-1028 [Abstract] [Full Text]
Toes, R. E. M., van der Voort, E. I. H., Schoenberger, S. P., Drijfhout, J. W., van Bloois, L., Storm, G., Kast, W. M., Offringa, R., Melief, C. J. M. (1998). Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells. J. Immunol. 160: 4449-4456 [Abstract] [Full Text]
Morgan, D. J., Kreuwel, H. T. C., Fleck, S., Levitsky, H. I., Pardoll, D. M., Sherman, L. A. (1998). Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity. J. Immunol. 160: 643-651 [Abstract] [Full Text]
Gnjatic, S., Cai, Z., Viguier, M., Chouaib, S., Guillet, J.-G., Choppin, J. (1998). Accumulation of the p53 Protein Allows Recognition by Human CTL of a Wild-Type p53 Epitope Presented by Breast Carcinomas and Melanomas. J. Immunol. 160: 328-333 [Abstract] [Full Text]
Shields, L. B. E., Gercel-Taylor, C., Yashar, C. M., Wan, T. C., Katsanis, W. A., Spinnato, J. A., Taylor, D. D. (1997). Induction of Immune Responses to Ovarian Tumor Antigens by Multiparity. Reproductive Sciences 4: 298-304 [Abstract]
Hart, D. N.J. (1997). Dendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response. Blood 90: 3245-3287 [Full Text]
Specht, J. M., Wang, G., Do, M. T., Lam, J. S., Royal, R. E., Reeves, M. E., Rosenberg, S. A., Hwu, P. (1997). Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases. JEM 186: 1213-1221 [Abstract] [Full Text]
Song, W., Kong, H.-L., Carpenter, H., Torii, H., Granstein, R., Rafii, S., Moore, M. A.S., Crystal, R. G. (1997). Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity. JEM 186: 1247-1256 [Abstract] [Full Text]
Vierboom, M. P.M., Nijman, H. W., Offringa, R., Voort, E. I.H. v. d., Hall, T. v., Broek, L. v. d., Fleuren, G. J., Kenemans, P., Kast, W. M., Melief, C. J.M. (1997). Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes. JEM 186: 695-704 [Abstract] [Full Text]
Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C., Sherman, L. A. (1997). Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes. JEM 185: 833-842 [Abstract] [Full Text]